US-based Formula Pharmaceuticals announced the acquisition of worldwide exclusive rights to an allogeneic, non-viral chimeric antigen receptor (CAR) technology platform which leverages cytokine-induced killer (C.I.K.) cells as immune effector cells. The platform has been developed at the Research Center Fondazione M. Tettamanti, a University of Milano-Bicocca affiliate.

“Formula’s C.I.K. CAR represents a proprietary, next-generation technology platform that is significantly differentiated from existing CAR-T approaches” said President and CEO, Maurits W. Geerlings. “In addition, Formula’s technology platform leverages non-viral transfection, which could make scale-up manufacturing significantly more practical and cost-effective as compared to viral transfection methods”.